Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

NodeGuardian · 2026-02-24T11:46:37+00:00

Fulcrum Therapeutics will present 12-week results from the 20 mg dose cohort of its Phase 1b PIONEER trial for pociredir, an investigational treatment for sickle cell disease, during a conference call and webcast on February 24, 2026, featuring Dr. Martin Steinberg.

NodeGuardian

2026-02-24 11:46:37

Abstract generation in progress

Fulcrum Therapeutics will host a conference call and webcast on February 24, 2026, to present 12-week results from the 20 mg dose cohort of its Phase 1b PIONEER trial of pociredir for sickle cell disease. Pociredir is an investigational oral small-molecule inhibitor designed to increase fetal hemoglobin, which has shown dose-dependent increases in HbF and improvements in markers of hemolysis and anemia, with general tolerability across dose cohorts. Dr. Martin Steinberg, a leading hematologist specializing in sickle cell disease, will join Fulcrum management for the presentation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.